A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic, Recurrent, Injectable Solid Tumors, with Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic Solid Tumors
Sponsor: Codiak BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT4058
U.S. Govt. ID: NCT04592484
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety and dose of CDK-002 alone in subjects with cancer that is considered advanced and/or has spread to other parts of the body. CDK-002 is an investigational study drug that is being developed for the potential treatment of cancer. This is a first-in-human study. CDK-002 is a drug designed to activate the immune system so that it tries to kill cancer cells. CDK-002 will be injected directly into cancer tumors. This may be done using a CT scan or an ultrasound to help guide the injection. Cancers include breast cancer, head and neck/oral cancers, skin cancers, melanoma, and thyroid cancer.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with an advanced or recurrent (comes back) solid tumor? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162